FOLH1 and posterior cortical atrophy: Also, radioisotope labeled PSMA ligands were applied for a diagnostical PSMA-based PET imaging, and in 2022 FDA approved a radiopharmaceutical 177Lu-PSMA-617 to treat PCa (Hoshi et al., 2023).